BR112017020016A2 - formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) - Google Patents

formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)

Info

Publication number
BR112017020016A2
BR112017020016A2 BR112017020016A BR112017020016A BR112017020016A2 BR 112017020016 A2 BR112017020016 A2 BR 112017020016A2 BR 112017020016 A BR112017020016 A BR 112017020016A BR 112017020016 A BR112017020016 A BR 112017020016A BR 112017020016 A2 BR112017020016 A2 BR 112017020016A2
Authority
BR
Brazil
Prior art keywords
ssao
salt forms
oxidase inhibitor
pharmaceutical salt
amine oxidase
Prior art date
Application number
BR112017020016A
Other languages
English (en)
Inventor
Savory Edward
Higginbottom Michael
Original Assignee
Proximagen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proximagen Ltd filed Critical Proximagen Ltd
Publication of BR112017020016A2 publication Critical patent/BR112017020016A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

a presente invenção refere-se a sais de mesilato e sulfato de mesilato de (4s)-4-isopropil-1,4,6,7-tetra-hidro-5h-imidazo[4,5-c]¬piridina-5-carboxilato de (3s)-tetra-hidrofuran-3-ila, e hidratos dos mesmos, e seu uso em medicina.
BR112017020016A 2015-04-24 2016-04-22 formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao) BR112017020016A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1507031.1A GB201507031D0 (en) 2015-04-24 2015-04-24 New pharmaceutical salt forms
PCT/GB2016/051119 WO2016170351A1 (en) 2015-04-24 2016-04-22 Pharmaceutical salt forms of an inhibitor of semicarbazide-sensitive amine oxidase (ssao)

Publications (1)

Publication Number Publication Date
BR112017020016A2 true BR112017020016A2 (pt) 2018-06-19

Family

ID=53488629

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017020016A BR112017020016A2 (pt) 2015-04-24 2016-04-22 formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)

Country Status (20)

Country Link
US (1) US10316034B2 (pt)
EP (1) EP3286190B1 (pt)
JP (2) JP2018513189A (pt)
KR (1) KR20170139045A (pt)
CN (2) CN107531702A (pt)
AR (1) AR104360A1 (pt)
AU (1) AU2016251707B2 (pt)
BR (1) BR112017020016A2 (pt)
CA (1) CA2979144A1 (pt)
DK (1) DK3286190T3 (pt)
EA (1) EA035668B1 (pt)
ES (1) ES2804155T3 (pt)
GB (1) GB201507031D0 (pt)
HK (1) HK1249906A1 (pt)
HU (1) HUE049985T2 (pt)
IL (1) IL254153A0 (pt)
MX (1) MX2017013049A (pt)
PT (1) PT3286190T (pt)
SG (1) SG11201707867WA (pt)
WO (1) WO2016170351A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain
GB201618029D0 (en) 2016-10-25 2016-12-07 Proximagen Ltd New process
CN108017634A (zh) * 2017-12-15 2018-05-11 清华大学 一种制备吡咯并多环衍生物的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4141899A (en) 1976-01-07 1979-02-27 Societa' Farmaceutici Italia S.P.A. 4,5,6,7-Tetrahydroimidazo-[4,5-c]-pyridine derivatives
IT1098015B (it) 1978-08-07 1985-08-31 Farmaceutici Italia Nuovi 4,5,6,7,-tetraidroimidazo-aperta par.quadrata 4,5-c chiusa par.quadrata-piridin-derivati
US6908926B1 (en) 1999-04-16 2005-06-21 Novo Nordisk A/S Substituted imidazoles, their preparation and use
JP2002542245A (ja) * 1999-04-16 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 置換イミダゾール、それらの製造および使用
AU2002214505A1 (en) * 2000-11-09 2002-05-21 Biovitrum Ab New use of 4, 5, 6, 7-tetrahydroimidazo-(4,5-c)pyridine derivatives
SE0004101D0 (sv) 2000-11-09 2000-11-09 Pharmacia Ab New use
WO2005082343A2 (en) * 2004-02-25 2005-09-09 La Jolla Pharmaceutical Company Amines and amides for the treatment of diseases
US20070066646A1 (en) 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
EP3461499A1 (en) 2006-06-07 2019-04-03 The Board of Trustees of The Leland Stanford Junior University Anti-leukocyte recruitment therapy for the treatment of recurrence of epileptic seizures
PT2334672E (pt) * 2008-09-16 2014-01-02 Proximagen Ltd Compostos novos i
US8633318B2 (en) * 2008-09-16 2014-01-21 Proximagen Ltd Compounds for treatment or prevention of inflammation, an inflammatory disease, or an immune or an autoimmune disorder
GB201004311D0 (en) * 2010-03-15 2010-04-28 Proximagen Ltd New enzyme inhibitor compounds
EA201490451A1 (ru) * 2011-09-14 2014-12-30 Проксимаген Лимитед Новые соединения - ингибиторы ферментов
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
GB201304526D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
US20160113893A1 (en) 2013-06-12 2016-04-28 Proximagen Limited New therapeutic uses of enzyme inhibitors
HUE042625T2 (hu) 2014-04-15 2019-07-29 Pecsi Tudomanyegyetem Szemikarbazid-szenzitiv amin-oxidáz gátlók fájdalomcsillapítóként való alkalmazásra traumás neuropátiában és neurogén gyulladásban
GB201507036D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Crystalline enzyme inhibitor compound
GB201507048D0 (en) * 2015-04-24 2015-06-10 Proximagen Ltd Treatment of pain

Also Published As

Publication number Publication date
CN107531702A (zh) 2018-01-02
EA035668B1 (ru) 2020-07-23
ES2804155T3 (es) 2021-02-04
AU2016251707A1 (en) 2017-10-05
DK3286190T3 (da) 2020-07-13
PT3286190T (pt) 2020-07-09
HK1249906A1 (zh) 2018-11-16
CA2979144A1 (en) 2016-10-27
EP3286190B1 (en) 2020-06-03
JP2021073256A (ja) 2021-05-13
IL254153A0 (en) 2017-10-31
AU2016251707B2 (en) 2020-02-20
GB201507031D0 (en) 2015-06-10
CN112851669A (zh) 2021-05-28
SG11201707867WA (en) 2017-11-29
MX2017013049A (es) 2017-12-08
JP2018513189A (ja) 2018-05-24
WO2016170351A1 (en) 2016-10-27
KR20170139045A (ko) 2017-12-18
US10316034B2 (en) 2019-06-11
EP3286190A1 (en) 2018-02-28
AR104360A1 (es) 2017-07-12
HUE049985T2 (hu) 2020-11-30
US20180111928A1 (en) 2018-04-26
EA201792121A1 (ru) 2018-03-30

Similar Documents

Publication Publication Date Title
MA45937A (fr) Inhibiteurs d'amino pyrimidine ssao
BR112016024545A2 (pt) derivados de pirazolo pirimidina e seu uso como inibidores de malt1
CY1119645T1 (el) Τριπεπτιδικοι αναστολεις πρωτεασης εποξειδικης κετονης
BR112017004141A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017020016A2 (pt) formas de sal farmacêutico de um inibidor de amina oxidase sensível a semicarbazida (ssao)
BR112018068278A2 (pt) derivado de 3-desóxi e suas composições farmacêuticas
CL2016000556A1 (es) Nanopartículas poliméricas terapéuticas y métodos para su elaboración y uso.
AR103680A1 (es) Inhibidores selectivos de bace1
BR112016012465A8 (pt) sal, método de preparação do sal e composição farmacêutica
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
BR112016009488A8 (pt) piperidil-etil-pirimidina substituída, seus usos, e composição farmacêutica.
BR112019006030A2 (pt) formas cristalinas e de sal de compostos agonistas de ppar
BR112017019653A2 (pt) derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd
BR112015022856A8 (pt) inibidores de protease de cetona de epóxi de tripeptídeo e dipeptídeo
BR112018003331A2 (pt) sondas para imagear proteína huntingtina
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
BR112017004134A2 (pt) ?sondas para imageamento de proteína de huntingtina?
BR112017004136A2 (pt) sondas para imageamento de proteína de huntingtina
BR112017019337A2 (pt) tratamento de dor
BR112017012406A2 (pt) formulação com relação fixa de insulina glargina/lixisenatida
BR112017017835A2 (pt) inibidores de grelina o-acil transferase
ITUA20161302A1 (it) "dispositivo di rotazione e posizionamento in particolare per oggetti globosi"
BR112014028121A2 (pt) n-etil-4-hidroxil-1-metil-5-(metil(2,3,4,5,6-pentahidroxihexil)amino)-2-oxo-n-fenil-1,2-dihidroquinolina-3-carboxamida
BR112017004000A2 (pt) formas cristalinas de 6-((6,7-dimetoxiquinazolin-4-il)óxi)-n,2-dimetilbenzofuran-3-carboxamida

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: BENEVOLENTAI CAMBRIDGE LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2719 DE 14-02-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.